Eplontersen Bests Placebo in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy Study
Cardiovascular Disease General Inborn Errors Of Metabolism Metabolic Disorders Neurologic Disorders News

Eplontersen Bests Placebo in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy Study

Topline results were announced from a phase 3 study evaluating eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). Hereditary ATTR is a severe, progressive and life-threatening disease caused by the abnormal formation and aggregations…